A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

NCT02283177 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed AML With FLT3 Activating Mutations

Interventions

DRUG: crenolanib
DRUG: cytarabine
DRUG: daunorubicin
DRUG: idarubicin

Sponsor

Arog Pharmaceuticals, Inc.